Delayed immunological reaction to Integra™ skin graft

Abstract

through lipid membranes. When topically applied, this agent is usually devoid of systemic AEs, although it can temporarily provoke contact sensitization. Glycopyrrolate has recently been evaluated in a topical formulation of 3.75% concentration in two double-blind, randomized, placebocontrolled, phase 3 trials for the treatment of hyperhidrosis. Our patients displayed excellent response and no recurrence during the follow-up period. Moreover, substantive improvement in malodour, maceration and discomfort was reported without related AEs. A plausible explanation of the disease improvement in our case series is that glycopyrrolate-induced sweat reduction may lessen bacterial colonization. Although this study is limited by the small number of patients, our experience supports that topical glycopyrrolate may represent a novel therapeutic approach in the management of PK.